Crinetics Pharmaceuticals Q2 2024 GAAP EPS $(0.94) Misses $(0.85) Estimate, Sales $399.000K Miss $510.000K Estimate
Portfolio Pulse from Benzinga Newsdesk
Crinetics Pharmaceuticals (NASDAQ:CRNX) reported Q2 2024 GAAP EPS of $(0.94), missing the $(0.85) estimate. Sales were $399.000K, missing the $510.000K estimate and down 59.62% from the same period last year.
August 08, 2024 | 8:39 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Crinetics Pharmaceuticals reported Q2 2024 GAAP EPS of $(0.94), missing the $(0.85) estimate. Sales were $399.000K, missing the $510.000K estimate and down 59.62% from the same period last year.
The significant miss on both EPS and sales estimates, along with a substantial year-over-year decline in sales, is likely to negatively impact CRNX's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100